{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T05:15:11Z","timestamp":1783487711888,"version":"3.55.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinology and Metabolism Clinics of North America"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.ecl.2020.05.001","type":"journal-article","created":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T08:29:33Z","timestamp":1594801773000},"page":"375-386","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["World Health Ozganization 2017 Classification of Pituitary Tumors"],"prefix":"10.1016","volume":"49","author":[{"given":"M. Beatriz S.","family":"Lopes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ecl.2020.05.001_bib1","series-title":"WHO classification of tumours of endocrine organs","year":"2017"},{"key":"10.1016\/j.ecl.2020.05.001_bib2","series-title":"WHO classification of tumours of the central nervous system","year":"2016"},{"key":"10.1016\/j.ecl.2020.05.001_bib3","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1126\/science.1062736","article-title":"Pituitary development: regulatory codes in mammalian organogenesis","volume":"295","author":"Scully","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.ecl.2020.05.001_bib4","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.gde.2004.08.006","article-title":"Transcriptional control of precursor proliferation in the early phases of pituitary development","volume":"14","author":"Zhu","year":"2004","journal-title":"Curr Opin Genet Dev"},{"key":"10.1016\/j.ecl.2020.05.001_bib5","first-page":"1281","article-title":"Pit-1 messenger ribonucleic acid is differentially expressed in human pituitary adenomas","volume":"77","author":"Friend","year":"1993","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2020.05.001_bib6","first-page":"1275","article-title":"Cell type-specific expression of the pituitary transcription activator pit-1 in the human pituitary and pituitary adenomas","volume":"77","author":"Asa","year":"1993","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2020.05.001_bib7","first-page":"1497","article-title":"Estrogen receptor expression in human pituitary: correlation with immunohistochemistry in normal tissue, and immunohistochemistry and morphology in macroadenomas","volume":"78","author":"Friend","year":"1994","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2020.05.001_bib8","first-page":"2165","article-title":"The transcription activator steroidogenic factor-1 is preferentially expressed in the human pituitary gonadotroph","volume":"81","author":"Asa","year":"1996","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2020.05.001_bib9","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/(SICI)1097-0029(19971015)39:2<168::AID-JEMT8>3.0.CO;2-H","article-title":"Transcription factors in normal and neoplastic pituitary tissues","volume":"39","author":"Lloyd","year":"1997","journal-title":"Microsc Res Tech"},{"key":"10.1016\/j.ecl.2020.05.001_bib10","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/modpathol.3880484","article-title":"Expression of GATA-2 in human pituitary adenomas","volume":"15","author":"Umeoka","year":"2002","journal-title":"Mod Pathol"},{"key":"10.1016\/j.ecl.2020.05.001_bib11","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1385\/EP:16:3:201","article-title":"Cytokeratin CK 7 and CK 20 expression in pituitary adenomas","volume":"16","author":"Coons","year":"2005","journal-title":"Endocr Pathol"},{"key":"10.1016\/j.ecl.2020.05.001_bib12","doi-asserted-by":"crossref","first-page":"4072","DOI":"10.1210\/jcem.86.9.7819","article-title":"Surgical management of GH-secreting pituitary adenomas: an outcome study using modern remission criteria","volume":"86","author":"Kreutzer","year":"2001","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2020.05.001_bib13","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/s41379-018-0167-7","article-title":"GATA3 immunoreactivity expands the transcription factor profile of pituitary neuroendocrine tumors","volume":"32","author":"Mete","year":"2019","journal-title":"Mod Pathol"},{"key":"10.1016\/j.ecl.2020.05.001_bib14","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s12022-015-9398-z","article-title":"The complementary role of transcription factors in the accurate diagnosis of clinically nonfunctioning pituitary adenomas","volume":"26","author":"Nishioka","year":"2015","journal-title":"Endocr Pathol"},{"key":"10.1016\/j.ecl.2020.05.001_bib15","series-title":"Tumours of the pituitary gland. WHO classification of tumours of endocrine organs","first-page":"34","article-title":"Gonadotroph adenoma","author":"Yamada","year":"2017"},{"key":"10.1016\/j.ecl.2020.05.001_bib16","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/ajcp\/106.1.16","article-title":"Application of catalyzed signal amplification in immunodetection of gonadotropin subunits in clinically nonfunctioning pituitary adenomas","volume":"106","author":"Sanno","year":"1996","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.ecl.2020.05.001_bib17","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/BF02739885","article-title":"Immunohistochemical heterogeneity within clinically nonfunctioning pituitary adenomas","volume":"6","author":"Yamada","year":"1995","journal-title":"Endocr Pathol"},{"key":"10.1016\/j.ecl.2020.05.001_bib18","series-title":"Tumours of the pituitary gland. WHO classification of endocrine tumors","first-page":"37","article-title":"Null cell adenoma","author":"Nishioka","year":"2017"},{"key":"10.1016\/j.ecl.2020.05.001_bib19","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1038\/s41379-018-0016-8","article-title":"Epidemiology and biomarker profile of pituitary adenohypophysial tumors","volume":"31","author":"Mete","year":"2018","journal-title":"Mod Pathol"},{"key":"10.1016\/j.ecl.2020.05.001_bib20","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s12022-014-9347-2","article-title":"Null cell adenomas of the pituitary gland: an institutional review of their clinical imaging and behavioral characteristics","volume":"26","author":"Balogun","year":"2015","journal-title":"Endocr Pathol"},{"key":"10.1016\/j.ecl.2020.05.001_bib21","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1007\/s11102-019-00981-9","article-title":"Clinical, pathologic, and imaging characteristics of pituitary null cell adenomas as defined according to the 2017 World Health Organization criteria: a case series from two pituitary centers","volume":"22","author":"Almeida","year":"2019","journal-title":"Pituitary"},{"key":"10.1016\/j.ecl.2020.05.001_bib22","series-title":"Tumours of the pituitary gland. WHO classification of endocrine tumors","first-page":"39","article-title":"Plurihormonal and double adenomas","author":"Kontogeorgos","year":"2017"},{"key":"10.1016\/j.ecl.2020.05.001_bib23","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/S0344-0338(11)80153-6","article-title":"Cushing's disease and hyperprolactinemia due to a mixed ACTH- and prolactin-secreting pituitary macroadenoma","volume":"187","author":"Mahler","year":"1991","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.ecl.2020.05.001_bib24","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00701-013-1890-y","article-title":"Plurihormonal pituitary adenoma with concomitant adrenocorticotropic hormone (ACTH) and growth hormone (GH) secretion: a report of two cases and review of the literature","volume":"156","author":"Rasul","year":"2014","journal-title":"Acta Neurochir (Wien)"},{"key":"10.1016\/j.ecl.2020.05.001_bib25","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1080\/01913120500323514","article-title":"Silent adenoma subtype 3 of the pituitary \u2013 immunohistochemical and ultrastructural classification: a review of 29 cases","volume":"29","author":"Horvath","year":"2005","journal-title":"Ultrastruct Pathol"},{"key":"10.1016\/j.ecl.2020.05.001_bib26","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1365-2265.2008.03514.x","article-title":"Silent subtype 3 pituitary adenoma: a clinicopathologic analysis of the mayo clinic experience","volume":"71","author":"Erickson","year":"2009","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.ecl.2020.05.001_bib27","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/modpathol.2015.151","article-title":"Silent subtype 3 pituitary adenomas are not always silent and represent poorly differentiated monomorphous plurihormonal pit-1 lineage adenomas","volume":"29","author":"Mete","year":"2016","journal-title":"Mod Pathol"},{"key":"10.1016\/j.ecl.2020.05.001_bib28","first-page":"243","article-title":"Multiple adenomas of the human pituitary. A retrospective autopsy study with clinical implications","volume":"74","author":"Kontogeorgos","year":"1991","journal-title":"J\u00a0Neurosurg"},{"key":"10.1016\/j.ecl.2020.05.001_bib29","series-title":"Tumors of the pituitary gland. WHO classification of endocrine tumors","first-page":"41","article-title":"Pituitary carcinoma","author":"Roncaroli","year":"2017"},{"key":"10.1016\/j.ecl.2020.05.001_bib30","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s12022-019-9568-5","article-title":"An institutional experience of tumor progression to pituitary carcinoma in a 15-year cohort of 1055 consecutive pituitary neuroendocrine tumors","volume":"30","author":"Alshaikh","year":"2019","journal-title":"Endocr Pathol"},{"key":"10.1016\/j.ecl.2020.05.001_bib31","series-title":"WHO classification of tumours of endocrine organs","first-page":"13","article-title":"Introduction","author":"Osamura","year":"2017"},{"key":"10.1016\/j.ecl.2020.05.001_bib32","series-title":"World Health Organization classification of tumours: pathology and genetics of tumours of endocrine organs","first-page":"10","article-title":"Pituitary tumors: Introduction","author":"Lloyd","year":"2004"},{"key":"10.1016\/j.ecl.2020.05.001_bib33","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1159\/000375448","article-title":"Typical and atypical pituitary adenomas: a single-center analysis of outcome and prognosis","volume":"101","author":"Chiloiro","year":"2015","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.ecl.2020.05.001_bib34","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s10143-016-0740-9","article-title":"Atypical pituitary adenomas: clinical characteristics and role of ki-67 and p53 in prognostic and therapeutic evaluation. A series of 50 patients","volume":"40","author":"Del Basso De Caro","year":"2017","journal-title":"Neurosurg Rev"},{"key":"10.1016\/j.ecl.2020.05.001_bib35","first-page":"226","article-title":"Incidence, hormonal distribution and postoperative follow up of atypical pituitary adenomas","volume":"23","author":"Yildirim","year":"2013","journal-title":"Turk Neurosurg"},{"key":"10.1016\/j.ecl.2020.05.001_bib36","first-page":"336","article-title":"Atypical pituitary adenomas: incidence, clinical characteristics, and implications","volume":"114","author":"Zada","year":"2011","journal-title":"J\u00a0Neurosurg"},{"key":"10.1016\/j.ecl.2020.05.001_bib37","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jocn.2016.09.014","article-title":"Predictors of aggressive clinical phenotype among immunohistochemically confirmed atypical adenomas","volume":"34","author":"Zaidi","year":"2016","journal-title":"J\u00a0Clin Neurosci"},{"key":"10.1016\/j.ecl.2020.05.001_bib38","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s00401-013-1084-y","article-title":"A\u00a0new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up","volume":"126","author":"Trouillas","year":"2013","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.ecl.2020.05.001_bib39","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1530\/EJE-11-0566","article-title":"Can we ever stop imaging in surgically treated and radiotherapy-naive patients with non-functioning pituitary adenoma?","volume":"165","author":"Reddy","year":"2011","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ecl.2020.05.001_bib40","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1136\/jnnp-2012-303194","article-title":"Short-term outcome of endoscopic versus microscopic pituitary adenoma surgery: a systematic review and meta-analysis","volume":"84","author":"Ammirati","year":"2013","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.ecl.2020.05.001_bib41","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/j.1365-2265.2012.04381.x","article-title":"Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment","volume":"76","author":"Raverot","year":"2012","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.ecl.2020.05.001_bib42","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1159\/000371806","article-title":"Aggressive pituitary tumors","volume":"101","author":"Chatzellis","year":"2015","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.ecl.2020.05.001_bib43","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nrendo.2014.64","article-title":"Aggressive pituitary adenomas--diagnosis and emerging treatments","volume":"10","author":"Di Ieva","year":"2014","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.ecl.2020.05.001_bib44","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1530\/EJE-18-0749","article-title":"Validation of a clinicopathological score for the prediction of post-surgical evolution of pituitary adenoma: retrospective analysis on 566 patients from a tertiary care centre","volume":"180","author":"Asioli","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ecl.2020.05.001_bib45","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-17-0796","article-title":"European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas","volume":"178","author":"Raverot","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ecl.2020.05.001_bib46","doi-asserted-by":"crossref","first-page":"3368","DOI":"10.1210\/jc.2017-00773","article-title":"Risk of recurrence in pituitary neuroendocrine tumors: a prospective study using a five-tiered classification","volume":"102","author":"Raverot","year":"2017","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2020.05.001_bib47","doi-asserted-by":"crossref","first-page":"C5","DOI":"10.1530\/ERC-17-0004","article-title":"From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal","volume":"24","author":"Asa","year":"2017","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.ecl.2020.05.001_bib48","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1038\/s41379-018-0110-y","article-title":"A\u00a0common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal","volume":"31","author":"Rindi","year":"2018","journal-title":"Mod Pathol"},{"key":"10.1016\/j.ecl.2020.05.001_bib49","doi-asserted-by":"crossref","DOI":"10.1007\/s00428-019-02655-0","article-title":"A\u00a0standardised diagnostic approach to pituitary neuroendocrine tumours (PitNETs): a European Pituitary Pathology Group (EPPG) proposal","author":"Villa","year":"2019","journal-title":"Virchows Arch"},{"key":"10.1016\/j.ecl.2020.05.001_bib50","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s11102-019-00988-2","article-title":"A\u00a0tale of pituitary adenomas: to NET or not to NET: Pituitary Society position statement","volume":"22","author":"Ho","year":"2019","journal-title":"Pituitary"},{"key":"10.1016\/j.ecl.2020.05.001_bib51","series-title":"WHO classification of tumours of endocrine organs","first-page":"24","article-title":"Lactotroph adenoma","author":"Nos\u00e9","year":"2017"},{"key":"10.1016\/j.ecl.2020.05.001_bib52","first-page":"617","article-title":"Silent corticotropic adenomas of the human pituitary gland: a histologic, immunocytologic and ultrastructural study","volume":"98","author":"Horvath","year":"1980","journal-title":"Am J Pathol"}],"container-title":["Endocrinology and Metabolism Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852920300281?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852920300281?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:45:17Z","timestamp":1760175917000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889852920300281"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":52,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S0889852920300281"],"URL":"https:\/\/doi.org\/10.1016\/j.ecl.2020.05.001","relation":{},"ISSN":["0889-8529"],"issn-type":[{"value":"0889-8529","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"World Health Ozganization 2017 Classification of Pituitary Tumors","name":"articletitle","label":"Article Title"},{"value":"Endocrinology and Metabolism Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ecl.2020.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}